HIV and Women

HIV Health Services Planning Council
February 22, 2016

Power Point by Monica Gandhi MD, MPH
Professor of Medicine, UCSF
Division of HIV, Infectious Diseases, and Global Medicine
Medical director, “Ward 86” HIV Clinic, San Francisco General Hospital
Adapted by Mary Lawrence Hicks, FNP
Women Die Younger Than Men from HIV in U.S.

Long-running gap may, however, be getting narrower

By Christine Gorman | November 10, 2015

Medications are keeping people with HIV alive longer than ever before, but women with AIDS tend to die at a younger age in the U.S. than men with the illness (see chart below). This long-standing gap may in part reflect differences in race among men and women with HIV, particularly as concerns access to health care. Nearly one in four people living with HIV in the U.S. are women.

Among newly infected women in 2010, there were five times more blacks than whites.

By comparison for that same year, there were almost equal numbers of black and white men who were newly infected with HIV.
Is HIV a feminist?

Epidemiology:
- Global and U.S.

HIV prevention in women
- Sex differences

HIV treatment in women
- Sex differences in outcomes, toxicities, pharmacokinetics

Primary care for women
- Breast and cervical cancer screening
When did prevalence of HIV in women worldwide become 50%?

1. 2000
2. 2008
3. 2012
4. 2014
5. Has not yet reached 50: 50 mark
Percentage of adults (15+ years) living with HIV worldwide who are female, 2006-2014

Reached 50:50 mark in 2008

Rates 59% in sub-Saharan Africa
WHY PEOPLE LIVING WITH HIV ARE BEING LEFT BEHIND

THE TOP 4 REASONS

01 Human rights violations, stigma and discrimination
02 Access to treatment and services
03 Gender-based inequalities
04 Criminalization and exclusion
Gender-based inequalities

- Infection rates among young women are twice as high as among young men in sub-Saharan Africa.

- In some settings, up to 45% of adolescent girls report that their first sexual experience was forced.

- In sub-Saharan Africa, only 15% of young women aged 15–24 are aware of their HIV status.

- In low & middle income countries, average HIV prevalence among female sex workers is ~12% (in 27 countries HIV prevalence among male sex workers is 14%).
What about HIV infections among women in the U.S.?
Adults and Adolescents Living with Diagnosed HIV Infection, by Sex and Transmission Category, Year-end 2012—United States and 6 Dependent Areas

Males
N = 702,273

- Male-to-male sexual contact: 7%
- Injection drug use (IDU): 12%
- Male-to-male sexual contact and IDU: 11%
- Other: <1%
- Heterosexual contact: 69%

Females
N = 229,176

- Heterosexual contact: 74%
- Injection drug use (IDU): 24%
Diagnoses of HIV Infection among Adults and Adolescents, by Sex and Race/Ethnicity, 2013—United States and 6 Dependent Areas

Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting.

a Hispanics/Latinos can be of any race.
Risks in U.S. women cluster with poverty, disempowerment

- HIV in women clusters with poverty\(^1,2\); interpersonal violence\(^3\); incarceration\(^4-7\); self-esteem, alcohol/drugs\(^8\)

Percentages of Stage 3 (AIDS) Classifications among Adult and Adolescent Females, by Race/Ethnicity and Year of Diagnosis 1985–2013—United States and 6 Dependent Areas

Note. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting.

a Hispanics/Latinos can be of any race.

b Includes Asian/Pacific Islander legacy cases.
WIHS: Black HIV+ Women Twice as Likely to Die of AIDS Than White HIV+ Women

- Other significant predictors of AIDS death: depression, peak HIV-1 RNA, nadir CD4+ cell count, HCV co-infection, substance use, < 95% adherence to ART
- Black race, depression predicted reduced adherence to ART, but black race remained associated with AIDS death after adjusting for adherence

Murphy K, AIDS 2013
Average Age at Death from HIV in the United States, 1987-2013

- Life expectancy for females (based on year of birth)
- Life expectancy for males (based on year of birth)

- FDA approves AZT, which is the first drug that works against HIV
- FDA approves the first protease inhibitors, which ushers in the age of successful combination therapy
- Study shows that the VaxGen vaccine fails to prevent infection with HIV
- Average age at death from HIV for males
- Average age at death from HIV for females

Graphic by Amanda Montañez, for Scientific American

What about HIV prevention in women?
Of the following interventions, which has the best evidence of efficacy in preventing HIV transmission to women?

1. Microbicides
2. Circumcision of the male partner
3. Male condoms
4. Giving the HIV-negative woman pre-exposure prophylaxis (PrEP)
5. Giving the HIV-positive male partner HIV treatment
Prevention only works if you know you’re at risk

“Women at risk for HIV acquisition frequently do not appreciate their risk. The HIV epidemic among US women is, in many ways, hidden from effective dialogue, both among the populations at risk and within the broader scientific community”¹

- In recent study (members of couple interviewed separately), 1 in 5 black women had a male partner at high risk (MSM or IVDU), but fewer than half knew²
- 74% heterosexual³
- Economic disempowerment – access to health care, condom negotiation
- 11% men concomitant relationships⁴
- Underestimate of bisexual behavior⁵
- 1 in 9 black men incarcerated⁶

Circumcision- conflicting data for women

- Parallel study of serodiscordant female partners in Rakai circumcision trial (60% ↓ to men\(^1\))\(^2\)

- Circumcision did not ↓ transmission to females over 24 mo (intercourse before wound healing?)

- Meta-analysis same findings\(^3\)

- Prospective study in African males - 40% reduction of transmission to females but not quite statistically significant (95% CI 0.35-1.10, p 0.10)\(^4\)

---

## Major RCTs of microbicides

<table>
<thead>
<tr>
<th>Trial location</th>
<th>Candidate microbicide</th>
<th>Efficacy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thailand, South Africa (Female sex workers)</td>
<td>Nonoxynol-9</td>
<td>Increased transmission</td>
<td>Van Damme. AIDS 2000</td>
</tr>
<tr>
<td>Africa, India</td>
<td>Cellulose sulfate</td>
<td>No protective effect</td>
<td>Van Damme. NEJM 2008</td>
</tr>
<tr>
<td>Africa</td>
<td>PRO2000 gel</td>
<td>No protective effect</td>
<td>McCormack. Lancet 2010</td>
</tr>
<tr>
<td>Africa, USA</td>
<td>BufferGel</td>
<td>No protective effect</td>
<td>Abdool-Karim. AIDS 2011</td>
</tr>
<tr>
<td>South Africa</td>
<td>1% tenofovir gel, coitally dependent, CAPRISA 004</td>
<td>39% reduction in HIV acquisition (54% in high gel adherers)</td>
<td>Abdool-Karim. Science 2010</td>
</tr>
<tr>
<td>South Africa</td>
<td>1% tenofovir gel, daily, VOICE</td>
<td>No overall protection, Some efficacy with PK detection</td>
<td>Marrazzo. NEJM 2015; Dai JID 2015</td>
</tr>
<tr>
<td>Africa</td>
<td>1% tenofovir gel, coitally dependent, FACTS 001</td>
<td>No protective effect, PK showed low adherence</td>
<td>Rees. CROI 2015</td>
</tr>
</tbody>
</table>
Does PrEP work as well in women as men?

1. Yes
2. No
3. No one knows
<table>
<thead>
<tr>
<th>8 major PrEP trials</th>
<th>Population/Setting</th>
<th>Intervention</th>
<th>Reduction in HIV Infection Rate, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>iPrEX[1] (N = 2499)</td>
<td>MSM, 11 sites in US, S. America, Africa, Thailand</td>
<td>▪ Daily oral TDF/FTC</td>
<td>44% (95% CI 15-63, p 0.005), no cis-women</td>
</tr>
<tr>
<td>Bangkok TFV Study[4] (N = 2413)</td>
<td>IDU (use in last year) in Bangkok, 20% female</td>
<td>▪ Daily oral TDF</td>
<td>Women 78.6% (p 0.03); men 37.6% (p 0.15)</td>
</tr>
<tr>
<td>VOICE[6] (N = 5029)</td>
<td>High-risk women, Africa</td>
<td>▪ Daily oral TDF ▪ Daily oral TDF/FTC ▪ 1% TFV gel ▪ 1% TDF gel &amp; daily oral TDF arm both stopped early (HR 0.34 gel with detectable drug) ▪ Daily TDF/FTC arm. no significant efficacy</td>
<td></td>
</tr>
<tr>
<td>IPERGAY and PROUD[7,8]</td>
<td>Both MSM, Ipergay (“on demand” PrEP) and PROUD (daily)</td>
<td>▪ Ipergay: 2 h before, 2-24h after, q24h ▪ PROUD: Daily</td>
<td>86% effective, no cis-women</td>
</tr>
</tbody>
</table>

Vaginal and Oral Interventions to Control the Epidemic (VOICE) MTN-003 trial: 5-arm trial to compare DAILY oral tenofovir, oral tenofovir/emtricitabine (Truvada), vaginal TFV gel, 2 placebo groups (5000 women)

- Oral tenofovir
  - Reported 2013, published 2015
- Oral Truvada®
  - Halted 2011, futility
- Vaginal tenofovir gel
  - Didn’t work either
- Placebo study product

Marrazzo J. NEJM 2015
VOICE: Adherence = Efficacy

<table>
<thead>
<tr>
<th>Study Drug</th>
<th>TDF</th>
<th>FTC/TDF</th>
<th>TFV Gel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Returned Pill or Applicator Counts</td>
<td>87</td>
<td>92</td>
<td>86</td>
</tr>
<tr>
<td>Self Report (7 days)</td>
<td>90</td>
<td>91</td>
<td>90</td>
</tr>
<tr>
<td>Adherence based on plasma TFV detection</td>
<td>30</td>
<td>29</td>
<td>25</td>
</tr>
</tbody>
</table>
Exposure/adherence may be particularly important in women

- Adherence may be more critical in women - tenofovir concentrations are higher in rectal than vaginal tissue¹
- Cumulative exposure of rectal tissue to tenofovir and tenofovir-emtricitabine 30x and 120x higher, respectively, vs vaginal tissue in same women²

¹Patterson KB. *Sci Transl Med* 2011;
²Louissaint NA *AIDS Res Hum Retroviruses*. 2013;
Safety Issues of PrEP in women

- Effect on **renal** function
  - Partners PrEP study: risk of small, non-progressive, reversible decline in glomerular filtration rate shown

- Effect on **bone mineral density**
  - Women are at higher risk than men for bone toxicities
  - Rates of osteopenia and osteoporosis are higher in HIV-infected patients than the general population

PrEP in women: Practical considerations

“PrEP-ception”: HIV- woman with HIV+ male partner taking PrEP before and during pregnancy

- Likely safe (PROMISE trial*)
- Male partner should be on ART treatment
- Ongoing PrEP-ception trial –HIV serodiscordant couples in 4 U.S. cities wishing to conceive- looking at adherence, condom use, teratogenicity

Likely safe in breastfeeding; does not interfere with hormonal contraceptives1

Along with usual screening in PrEP (HIV Ab, Hep B, renal function), pregnancy tests every 3 months.

*when combined with a protease inhibitor, this combination lead to poorer newborn outcomes. Appears to be safe when used alone.

1Callahan R, JAIDS 2015
What about treatment outcomes in HIV for women?
What is the percent of women being enrolled in publicly-funded ARV trials?

1. 12.5%
2. 16.7%
3. 22.5%
4. 33.7%
5. 50%
Women underrepresented in clinical trials....STILL

Women represented a median of 19.2% participants in ARV studies (387), 38.1% in VAX studies 47 (53) and 11.1% in CURE studies (104).

Curno M et al. JAIDS. 9/2015
Treatment outcomes by sex

Long story short:

- Women do better than men on ARVs globally, mainly from coming earlier to care through antenatal setting, adherence, less attrition
- Women do worse than men in the U.S. (Canada, Europe), mainly due to social determinants of health

In U.S., usual suspects in terms of social determinants of health

- Lower socioeconomic status
- Lower education levels
- Lower rates of having health insurance
- More food insecurity
- Competing priorities (childcare, etc.)
- Depression
- Substance use
- Domestic violence
- Distrust of the medical system
- Knowledge base of HIV/AIDS poor

GRACE (Gender, Race and Clinical Experience) Study – Higher side effects with many ARVS in women

• Landmark study: 67% women (84% black or Hispanic), comparing outcomes on Darunavir
• 32.8% of women (vs 23.2% men) discontinued ART
• Trend - worse virologic responses in women driven by higher d/c rates¹,²
• Conclusion (many studies): Real world and even clinical studies in HIV lose HIV-infected women: discontinuation rates high, adverse effects higher³

Pharmacokinetics: The explanation of sex differences?

• If women have higher ARV levels than men, could explain
  ➢ Increased risk of toxicities
  ➢ Improved outcomes
  ➢ Drug levels in treatment experienced patients may be particularly determinative of outcome

Primary care screening for HIV-infected women
The rate of which two cancers is not typically elevated in HIV infection?

1. Kaposi’s sarcoma and CNS lymphoma
2. Cervical cancer and anal cancer
3. B cell lymphoma and primary effusion lymphoma
4. Lung cancer and colorectal cancer
5. Prostate cancer and breast cancer
Breast and prostate cancer rates not typically higher in HIV infection

Table 2. Crude Cancer Type-Specific Incidence Rates and All-Cause Death Rates, by HIV Infection Status, NA-ACCORD, 1996-2009

<table>
<thead>
<tr>
<th>Event</th>
<th>Persons With HIV</th>
<th>Incidence Rate per 100 000 Person-Years</th>
<th>Uninfected Persons</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Persons, n</td>
<td></td>
<td>Persons, n</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Incidence Rate per 100 000 Person-Years</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>612</td>
<td>130.4</td>
<td>3</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>725</td>
<td>153.5</td>
<td>233</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>614</td>
<td>129.3</td>
<td>839</td>
</tr>
<tr>
<td>Anal cancer</td>
<td>285</td>
<td>60.1</td>
<td>22</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>173</td>
<td>36.4</td>
<td>510</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>220</td>
<td>46.3</td>
<td>201</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>159</td>
<td>33.5</td>
<td>36</td>
</tr>
<tr>
<td>Melanoma</td>
<td>78</td>
<td>16.4</td>
<td>268</td>
</tr>
<tr>
<td>Oral cavity/pharyngeal cancer</td>
<td>163</td>
<td>34.3</td>
<td>340</td>
</tr>
<tr>
<td>Death</td>
<td>17 534</td>
<td>3686.0</td>
<td>15 400</td>
</tr>
</tbody>
</table>

NA-ACCORD = North American AIDS Cohort Collaboration on Research and Design.

NA-ACCORD Study: 86 620 persons with HIV and 196 987 uninfected adults

Possible mechanism

- HIV binds to CD4 and to CCR5 or CXCR4 chemokine co-receptors
- Neoplastic breast cells commonly express CXCR4, but not CCR5
- In vitro, binding HIV protein to CXCR4 has been shown to induce self destruction of neoplastic breast cells
- Women with CXCR4-tropic HIV in large HIV+ women cohort had lower rates of breast CA

Hessol. PLOS One 2010; Goedert. JAIDS 2015
Breast and cervical cancer screening in HIV+ women

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Recommendation</th>
<th>Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammography</td>
<td>Perform annually in all women age 50 years or older</td>
<td>In women aged 40–49 years, providers should perform individualized assessment of risk for breast cancer and inform them of the potential benefits and risks of screening mammography</td>
</tr>
<tr>
<td>Cervical Pap smear</td>
<td>HIV-infected women should have a cervical Pap test performed upon initiation of care, and this test should be repeated at 6 months and annually thereafter if results are normal</td>
<td>Women with atypical squamous cells (both ASCUS and ASC-H [ASC, cannot rule out high-grade squamous intraepithelial lesion]), atypical glandular cells, low-grade or high-grade squamous intraepithelial lesion, or squamous carcinoma noted by Pap testing should undergo colposcopy and directed biopsy, with further treatment as indicated by results of evaluation</td>
</tr>
</tbody>
</table>
Summary

• Women doing more poorly in U.S. than men, may be closing gap
• PrEP works, but adherence may be especially important in women due to mucosal pharmacokinetics
• Bone safety with tenofovir and pregnancy monitoring in PrEP special considerations
• Women may have higher drug levels (PK) than men, leading to higher toxicities
• Breast cancer screening same as HIV-negative, but cervical cancer screening more frequently
Thank you

+ Dr. Monica Gandhi

+ Researchers studying all aspects of HIV in women

+ HIV infected women for continuing to teach us

+ The HIV Health Services Planning Council